Xeomin Now Available at DermaSpa MED
By contactus
November 08, 2011
Category: Uncategorized
Tags: Untagged

DermaSpa MED is among the first practices in the United States to gain exclusive access to XEOMIN®, a new Botox alternative. Merz Aesthetics on July 21, 2011 announced that the United States (U.S.) Food and Drug Administration (FDA) has approved XEOMIN® (incobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines, or frown lines between the eyebrows, in adult patients.

"The FDA approval of XEOMIN is a significant milestone for Merz Aesthetics and a promising addition to our entire aesthetics franchise," said Dennis Condon, President and Chief Business Officer of Merz Aesthetics, Inc. "We are confident that XEOMIN will provide patients and physicians with a new option for improving the appearance of glabellar lines."
"XEOMIN is a promising new option for both patients and physicians and we are encouraged by the response rates seen in the Phase III clinical trials," said Derek H. Jones, M.D., an investigator for the XEOMIN U.S. study, Clinical Associate Professor of Medicine at the University of California in Los Angeles, Calif., and Director of Skin Care and Laser Physicians in Beverly Hills, Calif.
For more information or to schedule an appointment contact DermaSpa MED at 805.739.0033 or use our Appt Request to schedule an appointment.